ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Flatiron Health Joins Veeva’s Product Partner Program to Accelerate Oncology Clinical Research

Partnership enhances oncology clinical trial efficiency through streamlined technology integration and long-term strategic collaboration.

Flatiron Health, a healthtech company transforming clinical research through solutions that integrate research into everyday care, today announced they will partner with Veeva Systems, a global leader in cloud software for the life sciences industry. As part of the partnership, Flatiron Health will join the Veeva Product Partner Program.

This collaboration builds on the integration of Flatiron Clinical Pipe™ and Veeva EDC (Electronic Data Capture), enhancing value and experience for both research sites and sponsor customers. As a cutting-edge EHR-to-EDC connector, Flatiron Clinical Pipe™ eliminates manual data entry of structured and unstructured data—improving site workflows, lowering data monitoring costs, and accelerating study timelines. Through this partnership, Flatiron and Veeva customers utilizing Flatiron Clinical Pipe™ will benefit from accelerated deployment and continually optimized configurations, ensuring seamless performance and a well-supported experience to meet evolving needs.

“Our collaboration with Veeva strengthens Flatiron’s ecosystem of partners in clinical research, reinforcing our position as an innovator in the use of technology to streamline clinical trials,” said Alex Deyle, General Manager of Clinical Research at Flatiron Health. “Flatiron Clinical Pipe, integrated with Veeva EDC, enables more streamlined data acquisition for clinical trials across a broader set of both research sites and sponsors—ultimately reducing burden, driving operational efficiencies, and accelerating research timelines.”

Additionally, the partnership establishes a long-term forum for strategic collaboration, allowing both companies to align on future innovations that streamline clinical trial data acquisition and drive greater value for customers.

Research published in the journal ESMO Real World Data and Digital Oncology, found that clinical research teams using Flatiron Clinical Pipe™ were able to accurately transfer thousands of data points, representing completion of hundreds of case report forms (CRF), with the average time of 37 seconds for a user to launch, complete, and submit a CRF, representing significant time savings for data entry over the course of a trial.1 Data transferred to the EDC with Flatiron Clinical Pipe™ completely mirrors source data in the EHR, reducing the need for source data verification on transferred data, allowing for greater efficiency for study teams.

About Flatiron Health

Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth

  1. Utility of automated data transfer for cancer clinical trials and considerations for implementation. Pfeffer, M. et al. ESMO Real World Data and Digital Oncology, Volume 7, 100112. DOI: 10.1016/j.esmorw.2025.100112

 

Flatiron and Veeva customers utilizing Flatiron Clinical Pipe™ will benefit from accelerated deployment and continually optimized configurations, ensuring seamless performance and a well-supported experience to meet evolving needs.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+0.00 (0.00%)
AAPL  268.47
+0.00 (0.00%)
AMD  233.54
+0.00 (0.00%)
BAC  53.20
+0.00 (0.00%)
GOOG  279.70
+0.00 (0.00%)
META  621.71
+0.00 (0.00%)
MSFT  496.82
+0.00 (0.00%)
NVDA  188.15
+0.00 (0.00%)
ORCL  239.26
+0.00 (0.00%)
TSLA  429.52
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.